INNOSTAR ORD A (SHH) EQSW Exp:
Shanghai InnoStar Bio-tech Co., Ltd. provides drug research and development services in China and internationally. The company offers screening and discovery, nonclinical assessment stage, and clinical development stage services in the areas of chemical products, biologics, cell and gene therapeutics, radiopharmaceuticals, and traditional Chinese medicines. The company was founded in 2010 and is … Read more
Market Cap & Net Worth: INNOSTAR ORD A (SHH) EQSW Exp: (688710)
INNOSTAR ORD A (SHH) EQSW Exp: (SHG:688710) has a market capitalization of $77.38K (CN¥567.72K) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #41528 globally and #4675 in its home market, demonstrating a 9.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying INNOSTAR ORD A (SHH) EQSW Exp:'s stock price CN¥57.59 by its total outstanding shares 9858 (9.86K).
INNOSTAR ORD A (SHH) EQSW Exp: Market Cap History: 2025 to 2026
INNOSTAR ORD A (SHH) EQSW Exp:'s market capitalization history from 2025 to 2026. Data shows growth from $59.32K to $77.38K (0.00% CAGR).
INNOSTAR ORD A (SHH) EQSW Exp: Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how INNOSTAR ORD A (SHH) EQSW Exp:'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 688710 by Market Capitalization
Companies near INNOSTAR ORD A (SHH) EQSW Exp: in the global market cap rankings as of March 18, 2026.
Key companies related to INNOSTAR ORD A (SHH) EQSW Exp: by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
INNOSTAR ORD A (SHH) EQSW Exp: Historical Marketcap From 2025 to 2026
Between 2025 and today, INNOSTAR ORD A (SHH) EQSW Exp:'s market cap moved from $59.32K to $ 77.38K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥77.38K | +30.44% |
| 2025 | CN¥59.32K | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of INNOSTAR ORD A (SHH) EQSW Exp: was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $77.38K USD |
| MoneyControl | $77.38K USD |
| MarketWatch | $77.38K USD |
| marketcap.company | $77.38K USD |
| Reuters | $77.38K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.